JOHNSON & JOHNSON’S RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) RECEIVES U.S. FDA PRIORITY REVIEW AS POTENTIAL FIRST-IN-CLASS EGFR- AND MET-TARGETED SUBCUTANEOUS TREATMENT FOR ADVANCED HEAD AND NECK CANCER

Reuters · 2d ago

Please log in to view news